VanEck Associates’s NeoGenomics NEO Stock Holding History

VanEck Associates’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30K	Sell	4,019 -902	-18%	-$9.49K	﹤0.01%	1351
2025 Q4	$58K	Buy	4,921 +2,619	+114%	+$28.3K	﹤0.01%	1350
2025 Q3	$18K	Buy	2,302 +705	+44%	+$4.94K	﹤0.01%	1376
2025 Q2	$12K	Buy	1,597 +237	+17%	+$1.91K	﹤0.01%	1369
2025 Q1	$13K	Hold	1,360	–	–	﹤0.01%	1354
2024 Q4	$22K	Sell	1,360 -364	-21%	-$5.65K	﹤0.01%	1336
2024 Q3	$23K	Sell	1,724 -782	-31%	-$12.2K	﹤0.01%	1309
2024 Q2	$35K	Hold	2,506	–	–	﹤0.01%	1305
2024 Q1	$39K	Buy	2,506 +132	+6%	+$2.04K	﹤0.01%	1292
2023 Q4	$38K	Buy	2,374 +402	+20%	+$6.58K	﹤0.01%	1302
2023 Q3	$24K	Sell	1,972 -202	-9%	-$3K	﹤0.01%	1329
2023 Q2	$35K	Hold	2,174	–	–	﹤0.01%	1322
2023 Q1	$38K	Buy	2,174 +125	+6%	+$1.78K	﹤0.01%	1322
2022 Q4	$19K	Buy	2,049 +600	+41%	+$5.59K	﹤0.01%	1363
2022 Q3	$12K	Buy	+1,449	New	+$14.4K	﹤0.01%	1334

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

VanEck Associates's NEO Position: Q1 2026 in Review

VanEck Associates reduced its NeoGenomics (NEO) stake by 18% in Q1 2026, selling an estimated $9.49K and leaving 4,019 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1351.

VanEck Associates first reported a position in NEO in Q3 2022 and has held it in 15 quarters since. The position peaked at $58K in Q4 2025. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

VanEck Associates held 4,019 shares of NeoGenomics worth $30K as of Q1 2026.
VanEck Associates sold 902 NeoGenomics shares in Q1 2026, an estimated $9.49K.
NeoGenomics made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #1351 holding.
VanEck Associates first reported a position in NeoGenomics in Q3 2022 and has held it in 15 quarters since.
VanEck Associates's NeoGenomics position peaked at $58K in Q4 2025.
253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.